You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 8,084,047

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,084,047 protect, and when does it expire?

Patent 8,084,047 protects XIIDRA and is included in one NDA.

This patent has thirty-five patent family members in fifteen countries.

Summary for Patent: 8,084,047

Patent landscape, scope, and claims:

Title:	Compositions and methods for treatment of eye disorders
Abstract:	The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Inventor(s):	Shen; Wang (San Mateo, CA), Oslob; Johan D. (Sunnyvale, CA), Barr; Kenneth (Boston, MA), Zhong; Min (Foster City, CA)
Assignee:	Sarcode Bioscience Inc. (Brisbane, CA)
Application Number:	12/508,367
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,084,047
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Dosage form; Delivery;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,084,047

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,084,047

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2444079	⤷ Subscribe	C02444079/01	Switzerland	⤷ Subscribe
Australia	2006247136	⤷ Subscribe
Canada	2609053	⤷ Subscribe
Canada	2960117	⤷ Subscribe
Canada	2985444	⤷ Subscribe
China	101175488	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.